Mark H. O'Hara, MD
Medical Oncology

Mark H. O'Hara, MD

Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Penn Medicine Provider

About me

  • Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

My education and training

  • SUNY Stony Brook School of MedicineMedical School
  • University of Pittsburgh School of MedicineResidency
  • University of Pennsylvania Health SystemFellowship

Spoken languages

English
English

Reviews

Average Rating

518 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
October 2026
Mark O'Hara is great
Anonymous
October 2026
He is a wealth of knowledge that is not seen belsewhere.
Anonymous
October 2026
Dr O'Hara is caring and compassionate. He is also very knowledgeable and has a great bedside manner.
Anonymous
October 2026
Very supportive and professional yet personable

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. O'Hara is a Penn Medicine provider.

Qualifications and experience

All conditions and treatments

Research

Publications

George B, Singh H, Devoe CE, Chung V, Hosein PJ, Hendifar A, Kim DW, Valerin JB, Bekaii-Saab T, Cardin DB, Hidalgo M, Kasi PM, Leal AD, Pelster M, Fei N, Weekes CD, O'Hara MH, George TJ, Kazmi SM, Mizrahi JD, Nair S, Maiers M, Kheoh T, Amato G, Xavier J, Snyder JP, Milaszewski MH, Cabana-Puig X, Perry JR, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, Pant S, Wainberg ZA, O'Reilly EM. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial , Nature Medicine: 2026


O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM; RASolute 302 Trial Investigators Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer , New England Journal of Medicine, 395(4): 2026


Reiss KA, Xia M, Akamandisa M, D'Andrea K, Wubbenhorst B, Lord CJ, Pettitt SJ, Tutt ANJ, Brown TJ, O'Hara MH, Schneider C, Teitelbaum U, Hannan Z, Hood R, Tondon R, Vonderheide RH, Domchek SM, Nathanson KL. Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial , JAMA Oncol: 2026


Till JE, Gal-Rosenberg O, Giliberto SG, Seewald NJ, Ballinger DG, Samberg HE, Yin MR, Wang QL, Cannas S, Kim KN, Tien K, Sawi M, Madineedi V, Furniss CS, Gocheva V, Nowak J, Brais LK, Yuan C, Rosenthal MH, Roses R, DeMatteo R, Lee MK, Vollmer C, Sagreiya H, O'Hara MH, Shemer R, Wolpin B, Dor Y, Carpenter EL. Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma , Clin Transl Med: 2026


O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma , J Immunother Cancer, 14: 2026,e012864


Barber-Rotenberg JS, Haas AR, Aggarwal C, O'Hara M, Hexner E, Pequignot E, Dowd E, Ndeupen S, Thai E, Chen F, Oner BS, Czuczman C, Gonzalez VE, Fraietta JA, Hwang WT, Chew A, Jadlowsky JK, Marshall A, Shea KM, Jiang Y, Cosey A, Ferthio R, Levine BL, Plesa G, Siegel DL, Young RM, Sheppard NC, Albelda SM, June CH, Tanyi JL. Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers , Mol Ther: 2026


Khalil DN, Gomez R, Regev A, Samaan F, Marouf Y, Budhu S, Hirschhorn D, Schulze I, Lavery JA, Ceglia N, Freeman SS, Maltez VI, Garcia JM, Suek N, Weng CH, Cabanski CR, Monette S, Romin Y, Li Y, Chaligne R, Yellin MJ, Keler T, Maurer DM, Flamar AL, Morgado-Palacin L, Mangarin LM, Harding JJ, Park W, Lyman JP, Maddock S, O'Hara MH, Abou-Alfa GK, Vonderheide RH, O'Reilly EM, Germain RN, Wolchok JD, Merghoub T. IL-10R inhibition induces neutrophil tumoricidal activity , Cancer Immunol Res: 2026


Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang WT, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadlowsky JK, Young RM, Berger SL, June CH, O'Hara MH. Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer , Cell Rep Med: 2025


Swami N, Hwang WT, Mamtani R, O'Hara MH, Chapin WJ. Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer , JAMA Netw Open, 8: 2025,e2515087


Amit U, Metz JM, Plastaras JP, Gheewala R, Teitelbaum U, Damjanov N, Vollmer C, Schneider CJ, Lee MK 4th, O'Hara M, Reiss-Binder K, Carpenter EL, Karasic TB, Konski A, Wileyto EP, Ben-Josef E. A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer , Cancer, 131: 2025,e35936